TENX
NASDAQ HealthcareTenax Therapeutics, Inc. - Common Stock
Biotechnology
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
๐ Market Data
| Price | $15.08 |
|---|---|
| Volume | 917,847 |
| Market Cap | 400.00M |
| Beta | 0.910 |
| RSI (14-Day) | 59.8 |
| 200-Day MA | $11.83 |
| 50-Day MA | $12.84 |
| 52-Week High | $19.40 |
| 52-Week Low | $5.77 |
| Forward P/E | -10.82 |
| Price / Book | 6.59 |
๐ฏ Investment Strategy Scores
TENX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (60/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (9/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TENX in your text
Paste any article, transcript, or post โ the tool will extract TENX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.